title: Preparation, characterization, in vitro release and degradation of cathelicidin-BF-30-PLGA microspheres.
abstract: Cathelicidin-BF-30 (BF-30), a water-soluble peptide isolated from the snake venom of Bungarus fasciatus containing 30 amino acid residues, was incorporated in poly(D,L-lactide-co-glycolide) (PLGA) 75∶25 microspheres (MS) prepared by a water in oil in water W/O/W emulsification solvent extraction method. The aim of this work was to investigate the stability of BF-30 after encapsulation. D-trehalose was used as an excipient to stabilize the peptide. The MS obtained were mostly under 2 µm in size and the encapsulation efficiency was 88.50±1.29%. The secondary structure of the peptide released in vitro was determined to be nearly the same as the native peptide using Circular Dichroism (CD). The ability of BF-30 to inhibit the growth of Escherichia coli was also maintained. The cellular relative growth and hemolysis rates were 92.16±3.55% and 3.52±0.45% respectively.
authors: Engineering Research Center of Biopolymer Functional Materials of Yunnan, Yunnan University of Nationalities, Kunming, Yunnan, China.
authors: Lili
authors: L
authors: Li
authors: Department of Radiation Oncology, Sichuan Cancer Hospital, Chengdu, Sichuan, China.
authors: Qifeng
authors: Q
authors: Wang
authors: Engineering Research Center of Biopolymer Functional Materials of Yunnan, Yunnan University of Nationalities, Kunming, Yunnan, China.
authors: Hongli
authors: H
authors: Li
authors: Engineering Research Center of Biopolymer Functional Materials of Yunnan, Yunnan University of Nationalities, Kunming, Yunnan, China.
authors: Mingwei
authors: M
authors: Yuan
authors: Engineering Research Center of Biopolymer Functional Materials of Yunnan, Yunnan University of Nationalities, Kunming, Yunnan, China.
authors: Minglong
authors: M
authors: Yuan
mesh_terms: D023181:Antimicrobial Cationic Peptides / Q000008:administration & dosage* / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects; D002478:Cells, Cultured; D002851:Chromatography, High Pressure Liquid; D002942:Circular Dichroism; D016503:Drug Delivery Systems; D004355:Drug Stability; D004655:Emulsions; D004730:Endothelium, Vascular / Q000166:cytology / Q000187:drug effects; D005079:Excipients; D006461:Hemolysis / Q000187:drug effects; D006801:Humans; D066298:In Vitro Techniques; D019344:Lactic Acid / Q000737:chemistry*; D008863:Microspheres; D010446:Peptide Fragments / Q000008:administration & dosage* / Q000494:pharmacology; D011100:Polyglycolic Acid / Q000737:chemistry*; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011108:Polymers; D012997:Solvents / Q000737:chemistry; D054804:Cathelicidins
chemical_list: D023181:Antimicrobial Cationic Peptides; D004655:Emulsions; D005079:Excipients; D010446:Peptide Fragments; D011108:Polymers; D012997:Solvents; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011100:Polyglycolic Acid; D019344:Lactic Acid; D054804:Cathelicidins